Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review

1Pulmonary vascular dysfunction is a broad term and may be central to several disease processes in the intensive care unit (ICU). Components include pulmonary endothelial dysfunction, altered lung microvascular permeability, vasoactive mediator imbalance, abnormal hypoxic vasoconstriction, pulmonary metabolic failure, microvascular thrombosis, and later, vascular remodelling. The resulting elevation in pulmonary vascular resistance (PVR) and pulmonary hypertension (PH) may increase the transpulmonary gradient, and the right ventricular "pressure overload" can in turn result in right ventricular (RV) dysfunction and failure. RV dysfunction may also result from volume overload or a primary RV pathology reducing contractility, including RV infarction and sepsis (Table 1).

2PH is defined at right-heart catheterization in the outpatient setting, with resting mPAP exceeding 25 mm Hg, and a PVR greater than 240 dyn.s.cm-5 (3 Wood units). At echocardiography, the presence of PH is suggested by the estimated RV systolic pressure (RVSP) exceeding 35 mm Hg (being severe if >50 mm Hg) (see later), and the pulmonary arterial acceleration time (PAT) may be shortened. Pulmonary arterial hypertension (PAH) defines PH not due to left-heart disease, with PAOP <15 mm Hg or without echocardiographic evidence of increased left atrial pressure. The severity of PH may depend on the chronicity: the actual pulmonary artery pressure generated will increase with time as the RV hypertrophies.

3RV dysfunction describes reduced RV contractility, which may be detected in several ways. At echocardiography, RV distention causes the intraventricular septum to deviate, with resulting paradoxic septal movement that impinges on LV function. RV function may be difficult to assess on echocardiography, especially in ventilated patients, and measurement of the descent of the RV base toward the apex (tricuspid annular systolic excursion, TAPSE) or RV fractional shortening may useful. Invasive monitoring may show a CVP exceeding the PAOP, or increasing CVP and PVR with a decreasing cardiac output (and mPAP may therefore decrease), and high right ventricular end-diastolic filling pressure is characteristic. By using an RV ejection fraction (RVEF) PAC, an increase in RV end-diastolic index and a reduction in RVEF are seen. We have defined RV failure to be the clinical result of RV dysfunction with the onset of hypotension or any resulting end-organ (for example, renal, liver, or gastrointestinal) dysfunction. Acute cor pulmonale (ACP) refers to acute right heart failure in the setting of acutely elevated PVR due to pulmonary disease.

4Pulmonary hypertension per se is frequently encountered in the ICU. It is commonly due to elevated pulmonary venous pressure in the setting of left-sided heart disease, or in patients with preexisting pulmonary vascular disease. It is well recognized after cardiothoracic surgery, in part related to the endothelial dysfunction seen with cardiopulmonary bypass (CPB). PH is also associated with sepsis; acute respiratory distress syndrome (ARDS) (with associated acute RV failure in 10% to 25% of cases), and in up to 60% of patients after massive pulmonary embolism (PE). PH is important to recognize in the ICU because its presence predicts increased mortality in these conditions as well as after surgical procedures. Mortality from cardiogenic shock due to RV infarction (> 50%) exceeds that due to LV disease. We therefore thought that a systematic review of the current evidence for the management of PH, resulting RV dysfunction, and failure in adult patients in the ICU, would be a useful addition to the critical care literature.

5The normal pulmonary circulation is a high-flow, low-pressure system. Unlike the left ventricle (LV), the thin-walled right ventricle tolerates poorly acute increases in afterload. This may lead to acute distention (Figure 1), with a resulting increase in oxygen consumption and reduction in contractility. The dilated RV, together with paradoxic intraventricular septal movement, lead to reduced LV filling, cardiac output (CO), and oxygen delivery. The principle of ventricular interdependence is important in most settings: superficial myocardial fibers encircle both ventricles; thus they are contained within the same pericardial cavity (except maybe after cardiac surgery), as well as sharing a septum, effectively existing "in series". This explains the decrease in LV output seen during positive-pressure ventilation and why RV pressure and volume overload cause diastolic dysfunction of the LV. Furthermore, because of the RV/LV interactions, the LV may markedly depend on atrial contraction for filling and may tolerate atrial fibrillation and vasodilating therapy particularly poorly.

6In addition, perfusion of the right coronary artery is usually dependent on a pressure gradient between the aorta and the right ventricle, which, in the setting of increased RV afterload and decreased coronary blood flow, may lead to RV ischemia, with further severe hemodynamic decompensation (Figure 2). In acute-on-chronic RV-pressure overload, the already-hypertrophied RV tolerates much higher pressures before decompensation, although the ability of the RV to augment CO in chronic PH may be restricted by its relatively "fixed" afterload. In any setting, the most common cause of increased RV afterload is an increase in PVR (Table 2).

7The gold standard for the diagnosis and management of PH and RV dysfunction in the ICU setting is considered by some to be through pulmonary artery catheterization (PAC), even though most of the information can be obtained noninvasively by echocardiography: the requirement for PAC in this population remains controversial. It must, however, be acknowledged that it provides the only direct continuous measurement of right-sided pressures and direct measurement of RV afterload, whereby, through measurement of cardiac output, pulmonary pressures and the pulmonary artery occlusion pressure (PAOP, the "wedge"), the PVR can be calculated (Figure 3). Overall outcomes are not improved when the PAC is used in general in critically ill patients; and complications do occur: the use in general is therefore declining. However, no studies have been done in the "pulmonary vascular" subpopulation. Alternative invasive hemodynamic measurements, such as CVP, may be useful surrogates for volume status in RV failure, by using the diastolic component of the CVP. Importantly, when monitoring CVP in patients with significant tricuspid regurgitation (TR), the variable V wave may be misleading, as it is included in the mean CVP calculation on most automated machines, and if rising, indicates RV overdistention. In the setting of cardiac surgery, one study shows that PAC use has reduced from 100% to 9% from 1997 to 2001, thought to reflect increased use of transesophageal echocardiography (TEE). In the setting of cardiac surgery, PAC may remain indicated for patients with PH and low CO and those predicted to have a difficult postoperative course, when a Swan introducer sheath may be inserted preemptively, or inserted for continuous monitoring after a diagnosis of RV dysfunction made with echocardiography. PAC is also a useful cardiac monitor with intraaortic balloon counterpulsation. Few data exist on PAC in other settings of pulmonary vascular dysfunction in the ICU, but one study suggests that PVR may be a poor indicator of pulmonary-circulation status in ventilated patients with ALI/ARDS. The role of echocardiography, both transthoracic (TTE) and TEE, is increasingly recognized in assessing RV function in many ICU settings and provides essential information about RV geometry and function. PA pressures may be assessed by estimating the systolic-pressure gradient across the tricuspid valve by using the modified Bernoulli equation, and although the correlation between invasive and sonographic measurement has been shown to be excellent in these studies, no studies have correlated PAC with echocardiographic measurements in the ICU population. In reality, a combination of invasive and noninvasive techniques is used. Biomarkers such as brain natriuretic peptide (BNP) are useful in monitoring chronic PAH, in risk-stratifying acute pulmonary embolism (see later), and in identifying ARDS-related pulmonary vascular dysfunction, although their role is less clear in other ICU settings.

8The diagnosis and management of acute pulmonary embolism (PE) warrants a specific mention, as it is a relatively common cause of acute RV failure in the ICU. Available therapies include thrombolysis and embolectomy, reducing the clot burden and acute mortality, as well as reducing the longer-term risk of chronic thromboembolic PH. Given that more than half of related deaths occur within an hour of the onset of symptoms, effective supportive treatment of shock is paramount. Patients presenting with acute PE are risk stratified according to the effects of elevated RV afterload: hypotensive patients and those with elevated cardiac biomarkers or echocardiographic indices of RV strain, or both, are deemed at increased risk, and thrombolysis is indicated.

9The management of PH and RV dysfunction in the ICU is challenging. No agreed algorithms exist, although treatment should aim to prevent pulmonary hypertensive crises and acute cor pulmonale. These comprise the spectrum of acute pulmonary vascular dysfunction and may result in cardiovascular collapse due to resulting biventricular failure. Management principles include the following: 1) optimization of RV preload, 2) optimization of RV systolic function, 3) reduction of afterload by reduction of increased PVR, and 4) maintenance of aortic root pressure to ensure sufficient right coronary artery filling pressure (Table 3).

10We performed a systematic review of the literature over the period from 1980 to 2010, by using set search terms, and the electronic database of the US National Library of Medicine and National Institute of Health (PubMed). After initial identification, abstracts were reviewed for relevance, and appropriate studies were included in the review. Reference lists of relevant articles were hand-searched for further studies and reports. The search was limited to publications in English. Studies were deemed suitable for inclusion according to the criteria listed and where the patient population and study design was defined; and the outcomes were limited to those depending on the specific GRADE question (see Additional file 1). The breakdown of articles obtained by the systematic search is shown (Table 4). After identification, relevant studies were included and subjected to a GRADE analysis to see whether we could make specific management recommendations.

11Management of PH with associated RV dysfunction in the ICU setting can be broken down into several treatment goals (Table 3). The first is to ensure adequate but not excessive RV filling or preload in the context of sufficient systemic blood pressure. The second goal is to maximize RV myocardial function, whether with inotropic support, rate or rhythm management, atrioventricular synchronization, or by using mechanical devices. The third is to offload the right ventricle by reducing the PVR with pulmonary vasodilators as well as by ensuring adequate oxygenation, avoiding hypercapnia and acidosis, and by minimizing mechanical compression of pulmonary vessels (for example, due to excessive airway plateau pressure). The fourth is to maintain adequate aortic root pressure to allow sufficient right coronary arterial perfusion.

12Systemic hypotension may relate to sepsis, overdiuresis, or progression of RV failure itself. Principles of volume management and vasopressor use are summarized.

13With a normal RV, RV ejection fraction is usually primarily dependent on RV preload. In the setting of excessive myocardial distention (by fluids), wall tension increases according to the Frank-Starling mechanism, and muscle fiber length is increased, beyond a certain point at which ventricular function will fail. This situation may be precipitated sooner in the setting of PH and RV dysfunction, in which both hypo- and hypervolemia may reduce cardiac output. In stable patients with PAH, high plasma volumes are associated with worse outcomes, but very few clinical studies have been performed in pulmonary vascular dysfunction, and the use of fluid loading remains controversial. Some animal studies show that fluids increase the cardiac index; others show that they worsen shock by inducing RV ischemia or decreasing LV filling or both as the result of ventricular diastolic interdependence (due to an increase in RV volume).

14In acute cor pulmonale after massive PE, increased filling may be at least initially required. In observational studies in sepsis, up to 40% of patients have evidence of RV failure, predominantly due to primary RV dysfunction. These patients have a higher CVP at baseline and are unable to augment stroke volume or perfusion pressure with fluid challenges alone, and so usually also require catecholamines.

15RV volume overload is a very important principle to recognize and treat promptly in RV failure. It may be identified by a rising V wave on the CVP trace, or by increased TR due to RV overdistention seen at echocardiography. In this situation of "backwards" heart failure, no further escalation of vasoactive agents is likely to be helpful (and may even be harmful), and management involves fluid removal (by using diuresis or hemofiltration) and avoidance of excessive RV afterload. Unmonitored fluid challenges are inadvisable in any setting of RV failure.

16Based on overall very-low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Close monitoring of fluid status according to effects on RV function is recommended. Initial carefully monitored limited volume loading may be useful after acute PE, but may also worsen RV performance in some patients with pulmonary vascular dysfunction, and vasoactive agents may be required.

17An essential goal is to maintain systemic blood pressure above pulmonary arterial pressures, thereby preserving right coronary blood flow: unlike left coronary artery perfusion, which occurs only during diastole (as aortic pressure exceeds LV pressure only during this period), perfusion of the right coronary artery usually occurs throughout the cardiac cycle, dominating in systole. It is understood that, as PVR approaches SVR, coronary perfusion will decrease, and if PVR exceeds SVR, coronary filling will occur only in diastole. By augmenting aortic root pressure by using vasopressors in the setting of increased RV afterload, RV ischemia can therefore be reversed. Vasopressors will, however, inevitably have direct effects on the pulmonary circulation as well as myocardial effects (Table 5).

18These include the catecholaminergic pressor, norepinephrine, and the noncatecholaminergic pressor phenylephrine. Their complex effects on the pulmonary circulation depend on the dose-related relative α- and β-adrenoreceptor stimulation as well as the degree and nature of RV dysfunction. All may potentially lead to tachydysrhythmias, diastolic dysfunction, myocardial ischemia, hyperlactatemia, and hypercoagulability.

19Norepinephrine (NE) exerts its systemic vasopressor effects through α-1 agonism. Activation of these receptors also causes pulmonary vasoconstriction, although the potential adverse effects on PVR are likely to occur only at high doses. Most evidence supporting this comes from animal studies in models of pulmonary vascular dysfunction, with NE at doses less than 0.5 μg/kg/min not increasing PVR. In persistent PH of the newborn, low-dose NE (0.5 μg/kg/min) reduces the PVR/SVR ratio. In adults with septic shock, higher doses of NE increase PVR/SVR, although without worsening RV performance. In patients with sepsis, PH, and associated RV dysfunction, NE increases SVR and improves the RV oxygen supply/demand ratio, although it does not increase RVEF and does increase PVR. Importantly, NE is positively inotropic through β-1 receptor agonism, thus improving RV/pulmonary arterial coupling, CO, and RV performance in studies of acute RV dysfunction due to PH, illustrated in a case report of acute PH after MVR surgery. In patients with chronic PH, NE reduces the PVR/SVR ratio, although it may not improve CI, which may relate to the "fixed" elevation in PVR.

20Phenylephrine (PHE) is a direct α-agonist. Its use improves right coronary perfusion in RV failure without causing tachycardia, although this benefit may be offset by worsening RV function due to increased PVR.

21Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: NE may be an effective systemic pressor in patients with acute RV dysfunction and RV failure, as it improves RV function both by improving SVR and by increasing CO, despite potential increases in PVR at higher doses.

22Arginine vasopressin (AVP) causes systemic vasoconstriction via the vasopressinergic (V1) receptor. Experimental studies have revealed vasodilating properties at low doses that include pulmonary vasodilatation through an NO-dependent mechanism via V1 receptors. This property manifests clinically as a reduction in PVR and PVR/SVR ratio. AVP has also been used as a rescue therapy in patients during PH crises, in which untreated equalization of systemic and pulmonary pressures may be rapidly fatal. At low doses (0.03-0.067 U/min), it has been used safely in sepsis, as well as in patients with acute PH and RV failure with hypotension after cardiac surgery and hypotension associated with chronic PH in several settings.

23AVP leads to a diuretic effect in vasodilatory shock, reduces the heart rate, and induces fewer tachyarrhythmias in comparison to NE. However, bradycardia may be encountered at high clinical doses. AVP may cause dose-related adverse myocardial effects at infusion rates exceeding 0.4 U/min, or even above 0.08 U/min in cardiogenic shock, which probably relate to direct myocardial effects, including coronary vasoconstriction.

24Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: In patients with vasodilatory shock and pulmonary vascular dysfunction, low-dose AVP may be useful in difficult cases that are resistant to usual treatments, including norepinephrine.

25The next major goal is to improve RV myocardial function by using inotropes. The use of mechanical support is discussed later. For sympathomimetic agents, desirable cardiac β1 effects at lower doses maybe offset by chronotropic effects precipitating tachyarrhythmias, as well as worsening pulmonary vasoconstriction at higher doses through α-agonism. Systemic hypotension may result from these agents and with phosphodiesterase inhibitors, which may necessitate co-administration of vasopressors.

26Few clinical studies of these agents have been done in patients with PH and RV dysfunction. Dopamine increases CO, although it may cause a mild tachycardia in patients with PH and increase the PVR/SVR ratio. Dopamine also tends to increase the heart rate and to have less-favorable hemodynamic effects in patients with cardiomyopathy than dobutamine, although it does not increase PVR at doses up to 10 μg/kg/min in animals with pulmonary vascular dysfunction. In patients with septic shock, PH, and RV dysfunction, dopamine improves CI without an increase in PVR. In the recent large randomized controlled study comparing dopamine with norepinephrine in patients with septic shock, dopamine increased arrhythmic events and, in patients with cardiogenic shock, increased the risk of death. In patients with primary RV dysfunction (without PH) due to septic shock, epinephrine improves RV contractility despite an 11% increase in mPAP. In animal studies, epinephrine reduces the PVR/SVR more than does dopamine. Isoproterenol has been used in RV failure primarily as a chronotrope after cardiac transplantation, although it may induce arrhythmias.

27At clinical doses up to 5 μg/kg/min in heart failure, dobutamine increases myocardial contractility, reduces PVR and SVR, and induces less tachycardia than does dopamine. It improves RV performance in patients with PH at liver transplantation, after RV infarction, and is used in PAH exacerbations. It is synergistic with NO in patients with PH. Experimentally, dobutamine has favorable pulmonary vascular effects at lower doses, although it leads to increased PVR, tachycardia, and systemic hypotension at doses exceeding 10 μg/kg/min. Given the adverse effects of systemic hypotension in these patients, it is important to anticipate and treat it with vasopressors when using dobutamine.

28An inodilator increases myocardial contractility while simultaneously causing systemic and pulmonary vasodilatation. Inodilators include the phosphodiesterase (PDE) III inhibitors and levosimendan.

29Several types of PDE are recognized: PDEIII usually deactivates intracellular cyclic adenosine monophosphate (cAMP), and PDE3 inhibitors therefore increase cAMP and augment myocardial contractility while dilating the vasculature. The selective PDEIII inhibitors include enoximone, milrinone, and amrinone. They are most suited to short-term use because of tachyphylaxis, and mild tachycardia is common. Milrinone is most frequently used and has been shown to reduce pulmonary pressures and augment RV function in many studies in patients with pulmonary vascular dysfunction. Enoximone improves RV function in pulmonary vascular dysfunction after cardiac surgery and in patients with decompensated chronic obstructive pulmonary disease (COPD). Enoximone leads to fewer postoperative myocardial infarctions than does dobutamine, which may relate to the resulting improved gas exchange when compared with dobutamine and GTN. Concerns regarding platelet aggregation with amrinone do not appear to arise with enoximone or milrinone after cardiac surgery. As with dobutamine, resulting reversible systemic hypotension means that coadministration with pressors is often necessary. Agents such as norepinephrine, phenylephrine or vasopressin are used, with the latter reducing PVR/SVR more than norepinephrine. PDEIII inhibitors may also improve RV function in chronic PH.

30Nebulized milrinone is increasingly used to manage PH crises in several settings. Through pulmonary selectivity, it results in less systemic hypotension and less V/Q mismatch compared with intravenous use in patients with PH after mitral valve replacement surgery. The combination of milrinone-AVP reduces PVR/SVR and may be preferable to milrinone-NE in RV dysfunction.

31Levosimendan sensitizes troponin-C to calcium and selectively inhibits PDE III, improving diastolic function and myocardial contractility without increasing oxygen consumption. It also acts as a vasodilator through calcium desensitization, potassium channel opening, and PDEIII inhibition. Levosimendan leads to a rapid improvement in hemodynamics, including reduction in PVR in patients with decompensated heart failure, with significant benefit on RV efficiency, with effects lasting several days. Levosimendan improves RV-PA coupling in experimental acute RV failure more than dobutamine. These effects have been shown clinically with improvements in RV function and reduction in PVR in ischemic RV failure, ARDS, and after mitral valve replacement surgery. In chronic PH, repetitive doses reduce mPAP and PVR from baseline and improve SvO2.

32Based on low-moderate-quality evidence (see Additional file 1), a WEAK recommendation can be made that low-dose dobutamine (up to 10 μg/kg/min) improves RV function and may be useful in patients with pulmonary vascular dysfunction, although it may reduce SVR. Dopamine may increase tachyarrhythmias and is not recommended in the setting of cardiogenic shock (STRONG recommendation based on high-quality evidence level).

33Based on mostly moderate-quality evidence (see Additional file 1), a STRONG recommendation can be made that PDE III inhibitors improve RV performance and reduce PVR in patients with acute pulmonary vascular dysfunction, although systemic hypotension is common, usually requiring coadmininstration of pressors. Based on low-quality evidence (see Additional file 1), a WEAK recommendation can be made that inhaled milrinone may be useful to minimize systemic hypotension and V/Q mismatch in pulmonary vascular dysfunction.

34Based on mostly low-quality evidence (see Additional file 1), a WEAK recommendation can be made that levosimendan may be considered for short-term improvements in RV performance in patients with biventricular heart failure.

35Physiologic coupling between the RV and the pulmonary circulation is a vital form of autoregulation of pulmonary circulatory flow (Figure 2). The RV is even less tolerant of acute changes in afterload than the LV, presumably because of the lower myocardial muscle mass. In sepsis, a reduction in PVR will increase the RV ejection fraction at no additional cost to cardiac output, but at levels beyond moderate PH, LV filling may be reduced, and ultimately cardiac output will decrease. Measures to reduce RV afterload may be nonpharmacologic (Table 3) or pharmacologic (Table 6).

36Specific pulmonary vasodilators may be useful both to reduce RV afterload and to manipulate hypoxic vasoconstriction in patients with severe hypoxia. Agents are classically subdivided according to their action on the cyclic GMP, prostacyclin, or endothelin pathways. In the nonacute setting, these agents also target remodeling of"resistance" pulmonary vessels and have revolutionized the care of patients with PAH. Importantly, however, the management with pulmonary vasodilators in chronic PH patients differs in several ways from that with acute pulmonary vascular dysfunction, notably in terms of rapid changes in RV volume status, and potential adverse hemodynamic effects of nonselective pulmonary vasodilators in unstable patients.

37Pulmonary vasodilators should be used after optimization of RV perfusion and CO. Systemic administration of pulmonary vasodilators may reduce systemic blood pressure, potentially reducing RV preload and worsening RV ischemia. Exclusion of a fixed elevated pulmonary venous pressure is important, as increased transpulmonary flow may precipitate pulmonary edema. Furthermore, nonselective actions of vasodilators may result in worsening ventilation/perfusion (V/Q) matching. This risk is reduced with the use of inhaled pulmonary vasodilators, with which the agent will reach vessels in only ventilated lung units.

38Adenosine increases intracellular cAMP via A2 receptor agonism, and when administered intravenously, acts as a potent selective pulmonary vasodilator because of its rapid endothelial metabolism. It has been used as a therapy for adult PH in some settings, including after cardiac surgery, but may elevate LV end-diastolic pressure and cause bradycardia and bronchospasm. It is currently therefore recommended as an alternative to NO and prostacyclin in dynamic vasoreactivity studies rather than as treatment for PH.

39Inhaled nitric oxide (NO) is a potent pulmonary vasodilator with a short half-life due to rapid inactivation by hemoglobin. This minimizes systemic vasodilatation, although it necessitates continuous delivery into the ventilator circuit. NO selectively reduces PVR and improves CO in PAH, secondary PH, acute PE, ischemic RV dysfunction, and postsurgical PH. NO also improves oxygenation, RVEF, and reduces vasopressor requirements in PH after cardiac surgery, especially in patients with higher baseline PVR, with no augmented effect seen at doses above 10 ppm in these patients. Use of NO (or inhaled PGI2) after mitral valve replacement surgery results in easier weaning from cardiopulmonary bypass and shorter ICU stays.

40NO has been shown to reduce PVR and improve CO in several studies in patients with acute RV failure due to ARDS and to improve oxygenation at lower doses than the RV effects. Administration of NO does need to be continuous for PVR reduction, and a potential exists for worsening oxygenation at excessive doses. The reduction in RV afterload, however, does not correlate with clinical-outcome benefits. Similarly, despite short-term improvements in oxygenation in ARDS, no studies show a survival benefit.

41NO provides synergistic pulmonary vasodilatation with intravenous prostacyclin, inhaled iloprost, and oral sildenafil. Limitations include accumulation of toxic metabolites, although this is not usually a clinically significant problem. Rebound PH with RV dysfunction may occur after weaning from NO, which may be reduced with PDE5 inhibitors.

42Prostanoids include prostaglandin-I2 (prostacyclin, PGI2) and its analogues, (iloprost) and prostaglandin-E1 (alprostadil, PGE1). An important difference between their formulations is their resulting half-life (Table 6). Prostacyclin is a potent systemic and pulmonary vasodilator, with antiplatelet and antiproliferative effects. In PAH, these agents reduce PVR, increase CO, and improve clinical outcomes, and are used in patients with NYHA III-IV symptoms.

43The use of prostanoids is most commonly described in ICU after cardiac surgery or transplantation. Intravenous prostacyclin, PGE1, inhaled prostacyclin, and iloprost all reduce PVR and improve RV performance in these settings, with inhaled agents being most selective. Intravenous PGE1 may cause marked desaturation in patients with lung disease. Inhaled prostacyclin has short-term equivalence to NO, and inhaled iloprost has been shown to be even more effective than NO at acutely reducing PVR and augmenting CO in PH after CPB and in PAH. Inhaled PGI2 also acutely improves pulmonary hemodynamics after acute massive PE. Although PGI2 impairs platelet aggregation, clinical bleeding was not increased in one study. The potential anticoagulant effect should be remembered, however, especially in patients after surgery and receiving concomitant heparin.

44In ARDS, intravenous prostacyclin reduces PVR and improves RV function, although it may increase intrapulmonary shunt. Inhaled prostacyclin and inhaled PGE1 improve oxygenation and reduce PVR in ARDS, with minimal effects on SVR. NO and intravenous PGI2 have been combined in ARDS with effective reduction of PVR without adverse effects.

45PDE5 inhibitors, including sildenafil and vardenafil, increase downstream cGMP signaling, potentiating the beneficial effects of NO (Figure 4). PDE5 inhibitors acutely reduce PVR, and increase CO and reduce PAOP more than does NO. These agents improve clinical end-points in PAH, where endothelial NO is reduced and PDE5 expression is upregulated. PDE5 inhibitor may also exert milrinone-like effects through PDEIII inhibition, augmenting RV function. Despite their relative pulmonary selectivity and rapid onset, however, adverse effects may include reduced SVR with potential effects on RV performance. Oral sildenafil has been used to reduce PVR effectively in well-selected patients with PH after cardiac surgery without reducing the SVR. Even a single dose may facilitate weaning from NO, also without reducing SVR. Sildenafil may also improve myocardial perfusion and reduce platelet activation as well as endothelial dysfunction after CPB. Oral sildenafil has been effective in patients with PH due to left ventricular systolic dysfunction, reducing PVR and increasing CO, although reducing the SVR. Sildenafil has also been used in selected patients with PH due to selected cases of chronic respiratory disease without worsening oxygenation or SVR. A single dose of 50 mg nasogastric sildenafil has been studied in a small cohort of consecutive ARDS patients, lowering MAP, and worsening oxygenation due to increased V/Q mismatch, although RV performance did improve. Intravenous sildenafil has been shown to reduce SVR and PVR in end-stage congestive heart failure patients, although it is not available commercially, and its use is not licensed in unstable patients (Table 6).

46Based on mostly moderate-quality evidence (see Additional file 1), the following STRONG recommendation is made: pulmonary vasodilators reduce PVR, improve CO and oxygenation, and may be useful when PH and RV dysfunction are present, notably after cardiac surgery.

47Based on mostly moderate-quality evidence (see Additional file 1), the ICU side-effect profile of intravenous pulmonary vasodilators may be less favorable than that of inhaled agents. The following STRONG recommendation is therefore made: Consideration should be given to the use of inhaled rather than systemic agents when systemic hypotension is likely, and concomitant vasopressor use should be anticipated.

48Based on mostly high-quality evidence (see Additional file 1), the following STRONG recommendation is made: give consideration for the use of NO as a short-term therapy to improve oxygenation indices but not outcome in patients with ARDS. Based on low-quality evidence (see Additional file 1), a WEAK recommendation is made that pulmonary vasodilators may also be useful treat PH associated with RV dysfunction in ARDS.

49Based on mostly low-quality evidence (see Additional file 1), the following WEAK recommendation is made: Oral sildenafil may reduce PVR and facilitate weaning from NO after cardiac surgery in selected patients with PH, without adverse effects on systemic blood pressure in well-selected patients.

50This encompasses RV "protective" strategies to avoid factors (Table 3) that may further increase PVR. Mechanical devices are also increasingly used to give a failing RV a bridge to recovery or transplantation.

51Important variables that may reduce pulmonary blood flow during ventilation include hypoxia, hypercapnia, and compression of the pulmonary vasculature at the extremes of lung volumes (Figure 4). Acute hypoxia leading to hypoxic pulmonary vasoconstriction is well described and may be augmented by many factors, including acidosis. Acute hypercapnia also leads to pulmonary vasoconstriction, although this may be attenuated with NO, and, when associated with high PEEP, leads to RV dilatation and reduced cardiac output in severe ARDS. A reduction in pulmonary blood flow occurs both at low volumes, such as in areas of atelectasis, and at high lung volumes, such as with increased airway plateau pressure (Pplat): Increased RV afterload, reduced venous return, and acute RV dysfunction may result. Both atelectasis and ventilation at high lung volumes should therefore be avoided in patients with RV dysfunction.

52Before the era of protective ventilatory strategies in ARDS, the incidence of acute RV failure was 60% and has since decreased to 10% to 25%. This is thought to reflect the change in ventilatory practice: lower Pplat reduces the incidence of RV failure. Prone ventilation may also reduce Pplat and pCO2 sufficiently to improve acute RV failure. In ARDS, transition to high-frequency oscillation leads to an increase in CVP and a minor decrease in cardiac output due to preload reduction, and RV function may decrease during recruitment maneuvers. In children after Fontan procedures, the hemodynamic effects of negative-pressure ventilation (NPV) are nicely illustrated by measuring pulmonary blood flow: after a switch from conventional intermittent positive pressure ventilation (IPPV) to NPV by using cuirass ventilation, pulmonary blood flow, stroke volume, and cardiac output increased up to 50%, and decreased to baseline when IPPV was reinstituted.

53Mechanical support for the RV may be appropriate in reversible settings or as a bridge to definitive treatment. RV-assist devices (RVADs) may be used in primary RV dysfunction and have been used with coexisting PH. There is, however, concern that pulsatile devices may cause pulmonary microcirculatory damage in PH. A pumpless "lung assist" device has been used in patients bridging to transplant. Extracorporeal membrane oxygenation (ECMO) has been used in severe PH, as a bridge to transplant, and after endarterectomy or massive PE. Intraaortic balloon counterpulsation (IABP) has been used for RV failure after CPB and transplantation, thought to improve CO by augmenting left coronary flow rather than by direct RV effects. Atrial septostomy creates a right-to-left shunt that improves left atrial filling and LV function while reducing RV end-diastolic pressure and improving RV contractility. It is sometimes used as a bridge to transplantation in severe PAH, although not in patients with very severe RV failure.

54Based on mostly very-low-quality evidence, the following WEAK recommendation is made: Mechanical therapies including ECMO and IABP may have a role as rescue therapies in reversible pulmonary vascular dysfunction or while awaiting definitive treatment.

55Pulmonary vascular and right ventricular dysfunction may complicate many ICU illnesses: the diagnosis may be difficult, and the acute management, challenging. Their presence is associated with a worse outcome. This review highlights that some recommendations can be made, despite limitations of the GRADE analysis. However, we do consider that "weak GRADE recommendations" could be interpreted as "management suggestions" and treated with appropriate caution. A further limitation is that several pathologies have been grouped together as one syndrome, although this relates to both the rarity of the syndrome and the lack of high-quality evidence: further research is desperately needed. In particular, only then will we learn whether PAH-targeted therapy such as use of PDE5 inhibitors or endothelin-receptor antagonists, so effective in idiopathic PAH, have a role in the ICU setting.

56• Pulmonary hypertension (PH) and associated right ventricular (RV) failure are associated with worse outcomes in critical care, and because of nonspecific presenting symptoms and signs, may be difficult to recognize: echocardiography is a very useful initial test, and invasive monitoring may be helpful in some cases for more continuous monitoring and accurate measurement of pulmonary vascular resistance.

57• Volume loading of the right ventricle may worsen its performance: all fluid challenges should be closely monitored.

58• It is essential to maintain adequate aortic root pressure to prevent the onset of RV ischemia. Vasopressors are useful in this setting, including low-dose norepinephrine as a first-line agent. Low-dose vasopressin may also be useful in some resistant cases but has adverse myocardial effects at higher doses. Potentially useful inotropes in RV failure include dobutamine and those with additional pulmonary vasodilating effects, including PDE III inhibitors, although co-administration with pressors is often necessary. The effects of any vasoactive drug may be unpredictable in an individual and require close clinical observation of circulatory performance, potentially assisted by echocardiography.

59• Pulmonary vasodilators are useful to reduce RV afterload in several ICU settings, including PH and RV failure after cardiac surgery. Systemic administration may worsen systemic hemodynamics and oxygenation because of ventilation-perfusion mismatching.

60• The use of mechanical therapies to manage acute PH and enhance RV performance is expanding, although with evidence currently limited to case series, and may be useful in experienced centers to ameliorate RV failure while awaiting definitive therapy.

61ACP: acute cor pulmonale; ARDS: acute respiratory distress syndrome; AVP: arginine vasopressin; cAMP: cyclic adenosine 3',5'-cyclic monophosphate; cGMP: cyclic guanosine 3',5'-cyclic monophosphate; CI: cardiac index; CO: cardiac output; COPD: chronic obstructive pulmonary disease; CPB: cardiopulmonary bypass; CVP: central venous pressure; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IABP: intraaortic balloon pump; LV: left ventricle; MVR: mitral valve replacement; NE: norepinephrine; NO: nitric oxide; PAC: pulmonary artery catheter; PAH: pulmonary arterial hypertension; PAOP: pulmonary arterial occlusion pressure; PDE: phosphodiesterase; PE: pulmonary embolism; PGE1: prostaglandin E1; PH: pulmonary hypertension; PHE: phenylephrine; PVR: pulmonary vascular resistance; RV: right ventricle; RVEF: right ventricular ejection fraction; RVF: right ventricular failure; SvO2: mixed venous oxygen saturation; SVR: systemic vascular resistance; TEE: transesophageal echocardiography; TR: tricuspid regurgitation; V/Q mismatch: ventilation/perfusion mismatch.

62LCP has received honoraria from Encysive Pharmaceuticals. SJW has received honoraria from Actelion Pharmaceuticals. SJB has received support for clinical trials from Pfizer, Astra Zeneca, and Baxter Healthcare.

63LCP and SJB conceived of the review and participated in its design. LCP and SJW carried out the literature search and drafted the initial manuscript. All authors read and approved the final manuscript.